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Abstract
Medication overuse headache (MOH) is defined in the latest ICHD-3 criteria as a
secondary headache caused by worsening of a pre-existing headache (usually a
primary headache) owing to overuse of one or more attack-aborting or pain-
relieving medications. MOH can be debilitating and results from biochemical and
functional brain changes induced by certain medications taken too frequently.
Various risk factors some modifiable, other non-modifiable (Multiple Gene Poly-
morphisms) have been hypothesised in MOH. Psychiatric co-morbidities in MOH
are noticeably (anxiety and depression) found to be co morbid disorders by more
than chance. This has to be managed effectively along with treatment strategies for
MOH for efficacious response to withdrawal treatment. Ample literature and clini-
cal evidence shown in prospective trials, that withdrawal therapy is the best treat-
ment for MOH. The mainstay of MOH treatment is not only to detoxify the patients
and to stop the chronic headache but also, most likely, to improve responsiveness to
acute or prophylactic drugs. Studies advocating prophylactic treatment with good
response to mainly topiramate and OnabotulinumtoxinA do exist, less prominent
for prednisolone, however, not recommended for every patient. Management may
be complex and must be done via MDT approach with involvement of specialists
when needed along with incorporating adequate treatment of acute withdrawal
symptoms, educational and behavioural programs to ensure patient understanding
of the condition and compliance. There are arguments on either sides of inpatient
and outpatient withdrawal for MOH patients dependent heavily on the individual
circumstances i.e. patient’s motivation, the duration of the overuse, the type of
overused drugs, possible previous history of detoxification failures and co morbid-
ities. Treatment trials are still required to determine for clinicians the best evidence-
based approach for helping these patients break their headache cycle.
Keywords: medication overuse, chronic migraine, chronic daily headaches,
rebound headaches, painkillers
1. Introduction
Medication-overuse headache (MOH) is defined by the International Classifica-
tion of Headache Disorders (ICHD) as a headache in patients with primary head-
ache disorders occurring on ≥15 days per month for >3 months, that is induced by
overuse of medications taken as symptomatic treatment for acute headaches.
In ICHD-3, chronic headache syndromes are described by professional consen-
sus as headache disorders that share traits with pre-existing headache syndromes,
happen for a specific duration of time (at least three months in Chronic tension-
type headache (CTTH), Chronic migraine (CM); or at least 12 months in Chronic
trigeminal autonomic cephalalgia (TAC)) and have an extra time-rule
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(e.g.headache days per month in CTTH and CM, or the absence of remissions for
greater than three months in TAC’s).
MOH occurs if the number of days of acute medicine taken for headache per
month exceeds a threshold level [1] i.e., 15 or more days for simple painkillers and
10 or more days for triptans, opioids and combination analgesics. The diagnosis of
MOH as per ICHD-3 is given as follows:
2. Diagnosis of medication-overuse headache
2.1 According to the ICHD-3 beta diagnostic criteria1, each of the criteria A–C
have to be fulfilled for the diagnosis of medication overuse headache
A
• Headache on ≥15 days/month
• Pre-existing headache disorder
B
• Overuse of acute and/or symptomatic headache medications for >3 months*C
• Not better represented by any other ICHD-3 diagnosis
*Regular consumption of tablets on ≥10 days/month for ergotamines, triptans,
opioids and mixture analgesics and on ≥15 days/month for paracetamol (also
recognised as acetaminophen), acetylsalicylic acid and NSAIDs.
As ICHD defines MOH as a secondary headache, one must identify the primary
headache disorder associated with it for example episodic or chronic migraine. The
classification identifies further sub-groups based on the substance misused (e.g.,
2.2.1.2 triptan-overuse headache). Many sufferers take more than one drug [2] or
are overusing combination analgesics and/or multiple drugs at different times
which are identified in the classification as headache attributed to numerous drug
classes (2.2.5). The comprehensive classification of MOH from ICHD-3 is given
here:
2.2 International classification of headache disorders third edition (ICHD-3)
criteria for medication-overuse headache (MOH)
2.2.1 Medication-overuse headache (MOH)
A.Headache happening on ≥15 days/month in a affected person with a pre-
existing headache disorder
B. Regular overuse for > three months of one or more drugs that can be taken for
acute and/or symptomatic treatment of headache
C.Not better represented by means of any other ICHD-3 diagnosis.
2.2.1.1 Ergotamine-overuse headache
A.Headache satisfying standards for 2.2.1 Medication- overuse headache
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B. Regular consumption of ergotamine on ≥10 days/month for >three months.
2.2.1.2 Triptan-overuse headache
A.Headache satisfying criteria for 2.2.1 Medication- overuse headache
B. Regular consumption of one or greater triptans, 1 in any formulation, on
≥10 days/month for >3 months.
2.2.1.3 Non-opioid analgesic-overuse headache
2.2.1.3.1 Paracetamol (acetaminophen)-overuse headache
A.Headache satisfying criteria for 2.2.1 Medication- overuse headache
B. Regular consumption of paracetamol on ≥15 days/month for > three months.
2.2.1.4 Non-steroidal anti-inflammatory drug (NSAID)- overuse headache
A.Headache satisfying criteria for 2.2.1 Medication- overuse headache
B. Regular consumption of one or extra non-steroidal anti- inflammatory drugs
(NSAIDs) (other than acetylsalicylic acid) on ≥15 days/month for >3 months.
2.2.1.4.1 Acetylsalicylic acid-overuse headache
A.Headache satisfying criteria for 2.2.1 Medication- overuse headache
B. Regular intake of acetylsalicylic acid on ≥15 days/month for >three months.
2.2.1.5 Other non-opioid analgesic-overuse headache
A.Headache satisfying criteria for 2.2.1 Medication- overuse headache
B. Regular intake of a non-opioid analgesic other than paracetamol or non-
steroidal anti-inflammatory tablets (including acetylsalicylic acid) on
≥15 days/month for> three months.
2.2.2 Opioid-overuse headache
A.Headache satisfying criteria for 2.2.1 Medication- overuse headache
B. Regular consumption of one or more opioids on ≥10 days/month for
>3 months.
2.2.3 Combination-analgesic-overuse headache
A.Headache fulfilling standards for 2.2.1 Medication- overuse headache
B. Regular consumption of one or more combination-analgesic medicines on




2.2.4 Medication-overuse headache attributed to combination drug classes not
individually overused
A.Headache satisfying standards for 2.2.1 Medication- overuse headache
B. Regular intake of any aggregate of ergotamine, triptans, non-opioid analgesics
and/or opioids on a total of ≥10 days/month for >3 months besides overuse of
any single drug or drug type alone.
2.2.5 Medication-overuse headache attributed to unspecified or unverified overuse of
numerous drug classes
A.Headache satisfying standards for 2.2.1 Medication- overuse headache
B. Both of the following: 1. regular consumption of any mixture of ergotamine,
triptans, non-opioid analgesics and/or opioids on ≥10 days/month for
>3 months
2.2.6 Medication-overuse headache attributed to different medication
A.Headache fulfilling standards for 2.2.1 Medication- overuse headache
B. Regular overuse, on ≥10 days/month for >3 months, of one or greater
medicines other than these described above, 1 taken for acute or symptomatic
cure of headache
3. Background and pathophysiology
MOH was first identified in 1951 in relation to overuse of ergotamine [3]. It was
in 1984 that relationship between analgesic consumption and exacerbation of head-
aches were recognised with improvement in headaches on stopping them [4]. It was
given the name as ‘drug-induced headache’ in the first classification of the headache
disorders (ICHD-1) [5]. The ICHD-2 described this as ‘medication-overuse head-
ache’ in 2004. The condition was said to be probable as the definitive diagnosis was
only given following reduction of headache days 2 months after withdrawal of the
overused medication [6]. The 2006 modification broadened the definition [7] by
abolishing the required improvement after discontinuation and this has persisted in
both ICHD-3 beta and ICHD-3 criteria [8].
4. Clinical characteristics
The headache of medication overuse is that of the primary headache disorder
[9]. Patients with migraines who overuse triptan will observe increase in the fre-
quency of pre-existing headaches to almost daily in frequency that exacerbates
intermittently and more so if a dose of triptan is missed. The patient gets in a vicious
circle with increasing headaches proportional to the triptans consumed. In the same
way patients with tension-type headache will report exacerbation of their feature-
less headaches [9]. A few people are able to differentiate between their primary
headaches and a constant dull and diffuse headache that they attribute as MOH. It
has been observed that MOH develops more quickly with triptan and resolves more
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quickly on withdrawal compared to combination and simple analgesics. This per-
ception was confirmed by a French study [10].
The diagnostic criteria for MOH do not fully demonstrate the complexity of
making the diagnosis of MOH. It is important to realise that medication overuse and
MOH are two different entities that can have different implications and outcomes.
Medication-overuse only signifies the number of days a person consumes painkiller
and not necessarily a cause for on-going headache. In certain chronic painful con-
ditions e.g., back pain; arthritis etc. there is medication overuse but no accompany-
ing headache. Another observation has been that not every individual will develop
headache with acute medication overuse [11]. It is not entirely clear why overuse
worsens headache in some and not the others. Considered a secondary headache
disorder, MOH should be identified by the type of medication being overused. The
primary headache disorder must also be identified.
5. Prevalence and general risk factors
Majority of research have reported the general prevalence of MOH in the normal
population to be 0.5–2.6% [12]. Higher rates have been seen in Russia (7.6%) [13] and
Iran (4.6%), where medication overuse is a lot more frequent than in other nations
[14]. However, no speculative reason or hypothesis has been provided for this.
The prevalence for MOH is 0.5–2.6% although it varies based on the availability
of painkillers over the counter (OTC) and hence reported much higher in Russia
(7.6%) and Iran (4.6%). The availability of OTC varies with codeine-based analge-
sics available in the UK, while barbiturates containing painkillers in the USA.
Figures from the third world countries such as India and Pakistan are difficult to
obtain considering all forms of painkillers are available over the counter with no
definitive prescription system existing in the country. The prevalence is less com-
mon in adolescents (0.3%–0.5%) than adults observed in two epidemiological stud-
ies in Norway and Taiwan [15, 16]. Overall females are affected more than males
(5:4) and those with chronic migraine have a very high incidence of medication
overuse (11–70%) much more than observed in the general population [17].
6. Risk factors
On the basis of current scientific knowledge, all pain medications have the
capacity to cause MOH. Dependency-like behaviour is most commonly seen in
patients who overuse opioids, although it is also seen in patients overusing triptans
[18–20]. Medication overuse was found to be an important risk factor for
chronification of primary headaches [21]. A study in the USA found majority of
patients with medication overuse were taking combined painkillers containing caf-
feine or opioids than simple painkillers [22]. They concluded that the risk of MOH is
less with simple painkillers although this does not prove a link between overuse and
a specific medication.
In a large prospective population-based study, Hagen et al. studied 25.596
patients who did not suffer from chronic daily headache at baseline but had MOH
11 years later (n = 201,0.8%) and the risk factors that were found to be associated
with development of MOH: regular use of tranquillisers, combination of chronic
musculoskeletal complaints, gastrointestinal complaints and hospital anxiety
depression scale (HADS) score > =11, physical inactivity and smoking [23].
Migraine headaches was more strongly linked with MOH than non-migraine head-




month, although it remains unclear as to whether this is because of a higher anal-
gesic intake or frequent migraine attacks. Some of the non-modifiable risk factors
for MOH include young age, female gender, family history of analgesic or substance
overuse and low education level. Smoking and physical inactivity were other risk
factors for MOH that were not associated with chronic daily headache without
medication overuse suggesting that the two conditions are phenotypically different
[23]. In 80% of patients with MOH, migraine is the underlying primary headache
disorder [24] and majority of remaining patients have tension-type headache or
more rarely post traumatic headache [25–27].
7. Main risk factors for MOH




Low degree of education 1.9(1.2–3.0)
Complaints that were self-disclosed
Chronic Musculoskeletal problems 1.9(1.4–2.7)
Gastrointestinal problems 1.6(1.1–2.2)










High daily Caffeine intake 1.4(0.8–2.5) (>540 mg versus ≤240 mg)
Figure shown are derived from population-based studies [23] in Norway
[15, 16], the USA [22] and China.CI, confidence interval; HADS, Hospital Anxiety
and Depression; MOH, medication-overuse headache; OR, odds ratio.
8. Pathophysiology
The pathophysiology of MOH remains unclear. The fact that patients with
migraine or tension type headache are more likely to develop MOH may mean that
the underlying mechanism for MOH could be related to a brain with these primary
headache disorders [28]. Patients with cluster headache (another primary headache
disorder) do not develop MOH in spite of regular painkillers unless they also suffer
from or have a family history for migraine [29]. It is possible that a genetic risk
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factor in a migrainous brain could make the person more susceptible to MOH
(Figure 1).
9. Genetic risk factors
9.1 Angiotensin-converting enzyme polymorphism
The renin-angiotensin system is well known for blood pressure control. Angio-
tensin II can cause increase in blood pressure and require Angiotensin-converting
enzyme (ACE) for its formation from Angiotensin I. It also has a role in regulating
neural plasticity [31] and its interaction with monoaminergic synaptic transmission
contributes towards dependence behaviour [32]. Polymorphism (insertion/dele-
tion) in the gene that encodes ACE may well play a role in the condition particularly
the D/D genotype [33].
9.2 Brain derived neurotrophic factor polymorphism
Brain-derived neurotrophic factor (BDNF) has been linked to substance overuse
[34, 35]. Certain BDNF genotypes (non G/G) [36, 37] are associated with increased
consumption behaviour for the painkillers than others.
9.3 Serotonin transporter polymorphism
Many affective disorders such as depression, anxiety and substance abuse are asso-
ciatedwith variants of SLC6A4 that encodes for SERT (Serotonin transporter) [38, 39].
Figure 1.
Current perception of the pathophysiology of medication-overuse headache (MOH) [30]. The understanding on
the pathophysiology of MOH entails transformation from and reversion to primary headache disorders,
displaying changes in physiological processes, functional connectivity, and structural changes of the central
nervous system, in patients with underlying genetic predisposition. Abbreviations: MOH: Medication-overuse
headache; CNS: Central nervous system (figure obtained from article ‘medication overuse headache: A widely




Patients with SLC6A4 variants that have MOH are extremely difficult to respond to
withdrawal therapy and have a high relapse rate following withdrawal [40].
9.4 Catechol-O-methyltransferase (COMT) polymorphism
COMT is an enzyme that metabolises catecholamines such as dopamine, adren-
aline and nor-adrenaline and influences pain modulation [41]. Certain genotypes of
COMTSNP (rs4680 and rs6269) have a low rate of relapse following withdrawal of
analgesics than others indicating its role [40].
10. Pain medications role
All forms of painkillers are associated with MOH although certain classes of
analgesics can cause the condition much quicker than others. For example patients
with triptan overuse develop MOH much quicker than opioids, ergotamine and
combination analgesics [42]. In the same way triptans withdrawal responds much
quicker and has a much lower relapse rate. This indicates that the underlying
pathophysiological mechanism may be medication specific. Platelets of those with
migraine and medication overuse have higher 5-HT2 receptors than those without
medication overuse [43]. The research has also shown a reduction of serotonin
levels and a reduction of the primary endogenous cannabinoids, anandamide and 2-
acylglycerol in those with Migraine and medication overuse compared to those
without it [44]. Research has also shown that those with MOH have a high con-
sumption of other medicines such as nasal decongestants, eye drops, laxatives,
tranquillisers and sleeping drugs.
11. Activation of trigeminovascular system
One of the pathways for head pain in migraine is activation of the trigeminal
primary afferent neurons innervating the intracranial and dural blood vessels.
Stimulation of these vessels have shown to induce pain similar to migrainous head-
ache [45, 46], although the exact underlying mechanism that activates the
trigeminovascular system remains unclear. Among possible explanations include
the spreading depression with subsequent neuronal depolarisation and activation of
the trigeminovascular system and release of chemicals that produce neurogenic
inflammation around the intracranial and dural blood vessels. Chronic use of para-
cetamol has shown to be associated with an increased activation of the nociceptive
pathway involved in headache. Hence it is proposed that prolonged exposure to
analgesics may lead to MOH via up-regulation of neural regulators of vasodilation
and neurogenic inflammation. It has been known for some time that sustained
systemic delivery of morphine exposure increases CGRP content in dorsal root
ganglion neurons [47, 48]. Plentiful studies documenting continuous, persistent
exposure of rats to triptans for a period of days was shown to result in a marked
increase in the numbers of trigeminal ganglion cell bodies expressing CGRP and a
modest increase in expression of substance P.
Imaging studies have demonstrated functional [49–51], structural [52, 53] and
metabolic [54] adjustments of the central pain network in patients with MOH. In a
voxel-based morphometric study [55] of individuals with MOH, grey matter vol-
ume was increased in the thalamus, midbrain, and striatum, and reduced in the
frontal regions [52] that resolved in sufferers who show clinical improvement of
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MOH [53]. Another study indicated that grey matter volume of the orbitofrontal
cortex estimated response to medication-overuse treatment [56].
Functional MRI studies have shown MOH associated hypoactivitiy in certain
cortical region including the right supramarginal gyrus, right inferior and superior
parietal area that constitute the lateral pain system [49, 50]. This was further
demonstrated in PET study where hypometabolism was also demonstrated in thal-
ami and cerebellar vermis [54]. These changes resolved at the end of the overuse
except in the orbito-frontal cortex [54]. It is to be emphasised that such changes are
not unique to MOH and can be seen to some extent in other headache disorders
(migraine) and pain conditions [55].
12. CO-morbidities
Co- morbidity is defined as the presence of one and more additional conditions
co-occurring with a primary condition. Psychiatric co-morbidities in MOH are
noticeably frequent and have been studied extensively since the earliest literature of
patients with MOH [57]. MOH and mood disorders such as anxiety and depression
are thought to be co morbid disorders by more than chance [57–60].
In the Norwegian BIMOH study, (double-blind pragmatic cluster randomised
controlled trial carried out among 50 general practitioners in Norway) sixty MOH
patients and 40 population controls were included. The MOH patients had signifi-
cantly higher headache disability and anxiety scores than the population controls.
Hospital Anxiety and Depression Scale (HADS) scores were collected in patients
with MOH (before and after a brief intervention) and controls. MOH patients were
found to show significantly higher HADS scores for anxiety [61].
In the European and Latina “COMOESTAS” trial, (694 patients with MOH from
six centres had been included, of whom 492 completed the study) in a seven-month
cohort study. The study used Hospital Anxiety and Depression (HAD) scoring and
found more than half (56%) of MOH patients had anxiety while 40% suffered from
depression [62]. Similar findings were seen in the ‘Eurolight’ trial conducted in ten
European countries. The association was considerably stronger in contrast to a
group of patients with migraine without overuse [63]. A study on Sodium Valproate
in Medication Overuse Headache (SAMOHA) found substantially higher number of
patients with moderate to severe anxiety compared to those with episodic migraine
or healthy controls [64]. Moreover, MOH are more likely to have one or more
psychiatric co-morbidities and some authors found a third of patient with clinically
relevant obsessive–compulsive disorders (OCD) [65].
Subclinical OCDmay be an additional risk factor for chronic headaches [64, 65].
MOH can also be associated to substance-related disorder spectrum,moreover since
MOH and dependence share common neurobiological pathways; noticeablyMOH
patients donot share commonpersonality characteristics seenwithdrug addicts [66, 67].
In a Chinese cohort, an association was found between MOH and metabolic
disturbances namely obesity and hypertension was shown in female patients [68]. A
Danish cross-sectional analysis confirmed an association between MOH and those
metabolic derangements (smoking, physical inactivity and obesity, although cau-
sality could not be proven [69]. Lastly, patients with chronic headache and MOH
present with a high prevalence of sleep symptomatology [70].
13. Treatment
There is adequate evidence that withdrawal therapy is the best treatment for




improve responsiveness to both acute and prophylactic medications [71]. The
following questions remain under discussion among headache experts:
1.Should preventive treatments be commenced at the time or following
withdrawal of the analgesics?
2.Should the withdrawal be abrupt or gradual?
3.Should this be done as out-patient or done through in-patient admission.
13.1 Preventive treatment before or following withdrawal
There is argument on both sides and researchers are divided with respect to
whether prophylactic medications are given at the time of withdrawal or after
withdrawal. Study conducted in Germany found all patients should be offered a
non-drug treatment and in the majority, additional preventive drug therapy. Taking
evidence from randomised controlled trials into consideration, topiramate or
OnabotulinumtoxinA should be offered as a treatment for this condition. About
50% of patients with chronic migraine and medication overuse will respond and
show a significant reduction in headache days [72]. Similar results were seen with
OnabotulinumtoxinA treatment in a large prospective study from Hull, UK.
OnabotulinumtoxinA significantly reduced the headache and migraine days whilst
increasing headache-free days and the benefit is equally seen in those with or
without co-existing medication overuse. We acknowledge the value of analgesic
withdrawal although we recommend that this can be achieved alongside preventive
treatment [73].
No study has ever compared abrupt withdrawal with tapered withdrawal in
prospective randomised trials; therefore, no formal evidence-based recommenda-
tion or guideline can be deduced. However, the majority of headache specialists
consider drug withdrawal to be more effective if done abruptly than
gradual [74–76].
13.2 Abrupt or gradual withdrawal
Abrupt withdrawal is recommended for overuse of triptans, ergots, paraceta-
mol, aspirin and NSAIDs and could be done in outpatients. Most patients have a less
protracted suffering and resolution of withdrawal symptoms is much quicker.
Those on opioids, barbiturates, benzodiazepines and combination analgesics a
tapered withdrawal is more appropriate as withdrawal symptoms are more severe.
Patients are warned that their headaches may get worse before getting better and
symptoms of nausea, vomiting, sleep disturbances, palpitations, restlessness and
anxiety are troublesome for a week to 10 days and in some cases may persist for up
to 4 weeks before showing improvement. The duration of worsening is shorter with
triptans (4.1 days) than ergotamine (6.7 days) and NSAID (9.5 days) [77].
A study in Italy of 137 patients aiming to study the effectiveness of an educa-
tional strategy (advice to withdraw the overused medication/s) with that of two
structured pharmacological detoxification programmes in patients with compli-
cated medication overuse headache (MOH) plus migraine concluded that inpatient
withdrawal is significantly more effective than advice alone or an outpatient strat-
egy in complicated MOH patients [78]. Another multicentre study (N = 376) on
MOH subjects in four European and two Latin American centres comparing in-
patient or out-patient detoxification programme with optional prophylaxis and a
follow up for 6 months concluded equal effectiveness of both strategies with or
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without prophylaxis [79]. Carlsen et al. (N = 72) in a prospective, outpatient study
randomised patients to two groups with one taking no analgesic or acute migraine-
medication and the other restricted to no more than two days of painkillers per
week. Patients were followed up for 12 months. The primary outcome was percent-
age reduction in headache days per month after 6 months. The outcome was better
in complete withdrawal and more patients reverted to episodic migraine in this
group [80].
13.3 Inpatient or outpatient
The decision has to be taken on individual circumstances that include the type of
overused medication, length of the overuse, patients’ motivation and history of
previous detoxification failures and presence of co-morbidities. Out-patient with-
drawal is more suited to simple analgesic, brief overuse period and highly motivated
patients [81]. Evidence in favour of inpatient withdrawal comes from an observa-
tional study from Austria showing statistically significant improvement of quality
of life, depression and anxiety at 6-month follow-up [82]. Alternatively a study
conducted in Milan has shown that direct comparison between inpatient with-
drawal and outpatient withdrawal treatment showed that both methods were
effective and revealed a significant reduction in headache days per month after
12 months and a decrease in the scores of migraine disability without superiority of
one method [83].
There is no standardised accepted protocol for both in-patient withdrawal.
Every clinic use their own method that does include intravenous dehydration,
complete stoppage of oral painkillers and treatment with anti-emetics and intra-
muscular painkillers as and when required with or without steroids [84–88].
With respect to corticosteroids, there is low evidence for change in various
headache outcome measures (i.e. use of rescue medication, days with severe or
moderate headache, days without headache, headache days, and frequency of
headache) [89, 90]. There is plentiful literature evidence to suggest that majority of
patients will get worse before they get better [91].
14. Prophylaxis
Early and effective prophylaxis remains the key to avoid chronification of epi-
sodic migraine. As nearly two-thirds of patients with chronic migraine have co-
existing medication overuse, the question remains largely unanswered whether
prophylaxis should commence before or after analgesic withdrawal. There are
arguments on both sides and the jury remains out as to which approach is better.
Some argue that patients with previous failure would show a good prophylactic
response following withdrawal [92]; others recommend prophylaxis at the same
time as withdrawal [93].
There are open-label studies showing improved outcome for using valproic acid
and topiramate in patients with chronic daily headache with medication overuse. A
double-blind study on topiramate in patients with chronic migraine and medication
overuse showed reduction of migraine days per month significantly higher in the
topiramate group (3.5 vs. 0.2 in placebo p < 0.05), although side effects were
considerably higher in the topiramate group (75% versus 37% in placebo) [94]. This
supported using topiramate use before analgesic withdrawal although the reduction
on headache days were not large enough to change it to episodic form. A similar




migraine days per month was significantly higher for topiramate than placebo (6.4
versus 4.7) [95].
In a Danish study consisting of 335 patients with MOH where abrupt detoxifi-
cation was initiated, the headache frequency was reduced by 67% in migraine
patients and by 37% in those with combined migraine and tension-type headache
after a 2-month observation period without prophylactic medication [92]. There are
randomised controlled trials to show that with patients affected by chronic migraine
and MOH suggest the use of onabotulinumtoxinA and topiramate without early
discontinuation. However, the quality of the data is limited due to the fact that it is
based on post hoc analysis [96]. Two further studies in the states have shown
improvement in headache days in patients with chronic migraine and medication
overuse treated with onabotulinumtoxinA and concluded that withdrawal prior to
prophylaxis may not be required in all patients with MOH [97].
15. Bridging therapy
Steroids and NSAID have so far been studied but their effectiveness remains
inconclusive. Few studies have used a short course of steroids as bridging treatment
with different outcomes. The first study from Brazil used a short course of oral
prednisolone in an out-patient setting. They studied 400 patients with daily head-
aches for longer than 6 months. Symptomatic medications were stopped suddenly
and prednisone was initiated in tapering doses during 6 days, followed by the
introduction of preventive treatment. The study found eighty-five per cent of the
patients experienced a reduction in headache frequency and no patients presented
severe attacks during the first 6 days. 10 day follow up, 46% of the patients experi-
enced at least 2 days without headache and 58% less intense attacks [98]. Another
German randomised, placebo-controlled, double-blind study showed efficacy of
prednisone for the treatment of withdrawal symptoms in patients with MOH
(N = 20). The total number of hours with severe or moderate headache within the
first 72 and 120 h was significantly lower in the prednisone group. The results show
that prednisone might be effective in the treatment of medication withdrawal
headache [99]. Another randomised, double-blind, and placebo controlled Norwe-
gian study negated the use of steroids as prophylaxis in MOH. Patients (N = 100)
were randomly assigned to prednisolone or placebo pills for six days. Study con-
cluded prednisolone has no effect on withdrawal headache in unselected patients
with chronic daily headache and medication overuse [100]. A brief period of pro-
phylaxis with naproxen 500 mg bd for 10–20 days has been recommended based on
experience [101], there are other doses used for different durations [102, 103].
16. Prognosis of withdrawal treatment
As a rule of thumb, overuse of acute treatment can lead to a poor prognosis of
chronic headache and lower quality of life by itself [104]. The outcome for MOH
patients withdrawing from their acute treatments has been reported in multiple
literature citations. An accepted endpoint as mentioned in many studies for good
response to therapy is a ≥ 50% reduction from baseline headache frequency and/or
headache index. Successful withdrawal was found in around 50–70% of MOH
patients after 1 year [105–113]. Managing to retain full withdrawal after 1 year was
found to be a good predictor for long-term success [114, 115].A successful with-
drawal leads to a better response for prophylactic treatment, even in patients with
little improvement in headache frequency [116].Tension-type headache have
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documented to have a higher relapse risk [105–107, 117, 118]. Patients who kept
overusing medication in the long-term had a poor response to withdrawal therapy
and had a higher frequency of chronic headache [114]. Risk factors for short term
relapse (1 year) were: high number of acute treatments, smoking, alcohol con-
sumption and return to overused drugs [119]. Patients withdrawn from triptans
have a lower relapse risk, while combined drug therapy had a higher relapse rate
[106, 118, 120]. Drugs with codeine, low self-reported sleep quality and high self-
reported bodily pain are probable predictors for poor outcome after 1 yr. [113]. A
prospective study from Germany followed 96 patients with MOH of which 75
completed 4 years. 26 patients (31%) relapsed within first six months and a total of
32 (41%) in the first year. The following three years only two more relapsed
totalling 34 (45%). The authors concluded that most of the patients who relapse do
that in the first year (94%) and the long-term success is dependent on the type of
primary headache and the type of overused painkiller [121].
Most recent evidence on the most effective treatment strategy comes from an
Open-label, randomised clinical trial to compare 3 treatment strategies for MOH
[122] which was conducted at the Danish headache Centre, Glostrup form October
2016 to June 2019. Random assignments (1:1:1 allocation) to 1 of the 3 outpatient
treatments consisted of [1] Withdrawal Plus Preventive treatment [2] Preventive
treatment without Withdrawal, or [3] Withdrawal with optional Preventive treat-
ment 2 months after Withdrawal. The Primary outcome was change in the headache
days per month after 6 months. Of 120 patients, 102 completed the 6 month follow-
up and the headache days per month were reduced by 12.3 (95% CI, 9.3–15.3) in the
withdrawal plus preventive group, by 9.9 (95% CI,7.2–12.6) in the preventive
group, and by 8.5 (95% CI 5.6–11.5) in the withdrawal group (P = 0.20). In the
withdrawal plus preventive group, 23 of 31 patients (74.2%) reverted to episodic
migraine, compared with 21 of 35 (60%) in the preventive group and 15 of 36
(41.7%) in the withdrawal group (P = 0.03). Moreover, 30 of 31 patients (96.8%)
were cured of MOH in the withdrawal plus preventive group, compared with 26 of
35 (74.3%) in the preventive group and 32 of 36 (88.9%) in the withdrawal group
(P = 0.03). These findings correspond to a 30% (RR, 1.3; 95% CI 1.1–.16) increased
chance of MOH cure in the withdrawal plus preventive group compared with the
preventive group (P = 0.03), therefore based on these findings, withdrawal therapy
combined with preventive medication from the start of the withdrawal is
recommended as the preferred management for MOH.
17. Conclusion
MOH is a common and worldwide problem with a prevalence of 1% in the
general population but accounts for nearly 11 to 70% in those with chronic daily
headaches, often under-recognised and un treated correlates with a significant
negative impact on the patient’s quality of life. Opiates and combination analgesics
carry an increased risk for MOH needs to be recognised and accepted as per litera-
ture. Among the multiple risk factors for the development of MOH, some are noted
to be modifiable and require MDT approach for attention and action. Anxiety and
depression are the most common co morbidities, and up to approximately 50% of
patients show dependence-type behaviours like tolerance or inability to control pain
medication usage.
Treatment trials are still required to determine for clinicians the best evidence-
based approach for helping these patients break their obnoxious headache cycle (?),
but intervention will require patient counselling, detoxification, and prevention




MOH for the general population and primary prevention strategies for patients and
providers. To achieve success in treatment, it is essential that the primary care
provider, nurse practitioner, pharmacist, and hospital doctors openly communicate
with the neurologist when MOH is suspected.
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